Market Place
Sourcing Support
All News #Library
Biotech
Syndax Announces Participation In March Investor Conferences
23 Feb 2026 //
GLOBENEWSWIRE
Syndax to Attend 2026 Guggenheim Emerging Outlook Biotech Summit
05 Feb 2026 //
GLOBENEWSWIRE
Syndax Presents At 44Th J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Revuforj Wins Best New Drug At Scrip Awards 2025
12 Dec 2025 //
GLOBENEWSWIRE
Syndax Showcases Menin Inhibition Leadership In Acute Leukemia
08 Dec 2025 //
GLOBENEWSWIRE
Syndax Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Dec 2025 //
GLOBENEWSWIRE
Syndax To Present Revuforj & Niktimvo Data at ASH 2025
03 Nov 2025 //
GLOBENEWSWIRE
Syndax To Host ASH Investor Event In-Person And Webcast On Dec
03 Nov 2025 //
GLOBENEWSWIRE
Syndax Gets FDA Nod For Revuforj® In NPM1 Mutated AML
24 Oct 2025 //
GLOBENEWSWIRE
Syndax`s Revuforj Added to NCCN Guidelines for Relapsed AML
19 Sep 2025 //
GLOBENEWSWIRE
Syndax Revumenib BEAT AML Data Out in JCO and EHA 2025
12 Jun 2025 //
GLOBENEWSWIRE
Syndax to Present Data on Revuforj and Niktimvo at EHA 2025
14 May 2025 //
GLOBENEWSWIRE
Incyte & Syndax Gain FDA Approval For New Cancer Treatment Sizes
15 Jan 2025 //
PR NEWSWIRE
US FDA approves Syndax`s blood cancer drug
16 Nov 2024 //
REUTERS
Syndax stock slips after AML drug hits midstage trial goal
13 Nov 2024 //
FIERCE BIOTECH
Syndax Announces Revumenib Abstracts at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Syndax to Present AGAVE-201 Data on Niktimvo at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Incyte & Syndax Publish AGAVE-201 Trial Data on Axatilimab in GVHD
18 Sep 2024 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.